EM
ERIN MENDELSOHN
VERTEX PHARMACEUTICALS INCORPORATED · Boston, MA · registered since 2024
Registered · LDAActive
At a glance
Registered since
2024
Senate LDA system
Clients
1
last 3 years
Filings
4
6 agencies contacted
Activity
filings by quarter
Works on
Specific issues
Federal policies impacting pharmaceutical development, approval, and reimbursement; Copay accumulators and maximizers, HELP Copays Act (H.R. 830/S. 1375); Alternative Funding Programs; Unmet medical need in acute pain; Barriers to patient access of non-opioid pain medicines; General education about kidney disease, including APOL-1; Cystic Fibrosis; Sickle cell disease; Innovations in Type 1 diabetes treatments.
Unmet medical need in acute pain; H.R.7421/S.3832 - The Alternatives to PAIN Act; Implementation of Public Law No: 117-328 sec. 4135 NO PAIN Act; Medically necessary fertility treatments for patients undergoing fully myeloablative conditioning; CMMI demo focusing on sickle cell disease.
Access to non-opioids in DoD/Tricare (H.R.8774/S.4921 - Department of Defense Appropriations Act, 2025); Access to non-opioids in VHA and general support for clinical trial operations at VHA to address high prevalence diseases and conditions (H.R.8580/S.4677 - Military Construction, Veterans Affairs, and Related Agencies Appropriations Act, 2025); Access to non-opioids for Medicare beneficiaries and education about risk of kidney disease amongst minority populations (H.R.9029/S.4942 - Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2025).
Federal policies impacting pharmaceutical development, approval, and reimbursement; Copay accumulators and maximizers, HELP Copays Act (H.R. 830/S. 1375); Alternative Funding Programs; Unmet medical need in acute pain; Barriers to patient access of non-opioid pain medicines; Genetic kidney disease, including APOL-1; Ex-US access to innovative medicines; Cystic Fibrosis; Sickle cell disease.
Unmet medical need in acute pain; H.R.7421/S.3832 - The Alternatives to PAIN Act; Implementation of Public Law No: 117-328 sec. 4135 NO PAIN Act; Medically necessary fertility treatments for patients undergoing fully myeloablative conditioning.
General education about federal policies impacting pharmaceutical development, approval, and reimbursement; Education about non-opioid pain therapies and Medicare beneficiary access to non-opioid medicines; Medicaid Program; Misclassification of Drugs, Program Administration and Program Integrity Updates Under the Medicaid Drug Rebate Program.